drugset / Trial / NCT01583816

Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

NCT01583816

Phase 2 Completed 218 enrolled Spirig Pharma Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions

Timeline

Start
2012-05
Primary completion
2013-11
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule 0.01 % Topical
Subject Resiquimod Small molecule 0.03 % Topical

Indications